Difference between revisions of "Dutasteride (Avodart)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
|||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 11 | + | * 2001-11-20: Initial FDA approval for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland. |
| − | * | + | * 2011-06-09: New FDA Limitation of Use: AVODART is not approved for the prevention of prostate cancer. |
| − | + | ||
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Avodart | *'''Brand name:''' Avodart | ||
Revision as of 21:34, 4 May 2023
General information
Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Competitively inhibits type 1 and 2 5 alpha-reductase isoenzymes by forming a stable enzyme complex with them.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Dutasteride (Avodart) package insert pages 26-29[1]
- Dutasteride (Avodart) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2001-11-20: Initial FDA approval for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland.
- 2011-06-09: New FDA Limitation of Use: AVODART is not approved for the prevention of prostate cancer.
Also known as
- Brand name: Avodart